Evaluation of the potential antimalarial effect of ivermectin: a controlled human malaria infection trial – PREMIVER (PREvention of Malaria with IVERmectin)

Project start
Institution: Institut für Tropenmedizin, Reisemedizin, Humanparasitologie, Universitätsklinikum Tübingen
Applicant: Prof. Dr. Peter G. Kremsner
Syringe in lieu of mosquito: malaria sporozoites are prepared for the experimental infection.

Half a million people, especially children in tropical Africa, die every year of Plasmodium falciparum malaria. The successful use of ivermectin against malaria would be a groundbreaking step forward to control malaria. Ivermectin is widely used for the treatment and control of neglected tropical diseases as onchocerciasis and lymphatic filariasis.

Prophylactic effects of ivermectin on malaria sporozoites have been demonstrated in vitro and in animals. However, proof and confirmation of a prophylactic ivermection effect in man is lacking.

In this study, the effect of ivermectin on malaria sporozoites is investigated with a controlled human malaria infection trial: 12 volunteers are infected experimentally with sporozoites of P. falciparum. 8 volunteers are given ivermectin (400mcg/kg) 2 hours before the infection, 4 volunteers receive placebo.

The endpoint of the study is the appearance of malaria parasites in the blood. This human malaria infection model was established at the Institute of Tropical Medicine in Tuebingen, Germany, and is the only method to evaluate the efficacy of a medicament or a vaccine in a rapid, reliable way with only a small group of volunteers. The results of this experimental infection study will represent a significant contribution to the appraisal of ivermectin as a means of malaria control.

Here you can get further information.